Mn-SOD与抗癌胚抗原单链抗体基因的融合及高效表达

将Mn-SOD与抗癌胚抗原(CEA)单链抗体基因(ScFv gene)融合,重组到含T7启动子的表达载体pET-22b(+)中,构建表达质粒pETMnSOD-ScFv,并转化大肠杆菌BL21(DE3),进行高效表达,表达物占菌体可溶性总蛋白的24%。SDSPAGE和蛋白质印迹图谱显示表达物分子量为45kD与融合基因编码蛋白质的理论值相符。该蛋白质在大肠杆菌中为分泌型表达有利于纯化。RIA测定表明表达产物能特异性的与抗原CEA结合,同时邻苯三酚法测定也表明表达产物具有SOD酶的活性,该融合蛋白为分泌CEA肿瘤的靶向性治疗提供新的途径。     

蓝舌病毒HbC3对几株人和动物肿瘤细胞的感染特性研究

用BTV-HbC3感染人肺癌SPC-A-1细胞,人宫颈癌HeLa细胞,人星型胶质瘤U251细胞,小鼠星形胶质瘤C6细胞及人胚肺HEL细胞后,观察细胞病变效应(CPE);运用透射电镜技术及琼脂双扩散试验检测BTV-HbC3对各种不同肿瘤细胞及人胚肺HEL细胞的感染性;并用RT-PCR技术检测蓝舌病毒的增殖情况.结果显示,BTV-HbC3对正常HEL不感染,但能在不同来源的某些肿瘤细胞中选择性增殖,产生不同程度的细胞病变效应(CPE)及调亡现象,终致肿瘤细胞死亡.其中以人肺癌SPC-A-1细胞对其最为敏感.因此,初步认为BTV-HbC3株能靶向性杀死某些肿瘤细胞,从而为深入开展BTV-HbC3靶向性抗肿瘤的研究提供了第一手实验室依据.     

慢病毒靶向携带Survivin siRNA抗肺腺癌的体内研究

目的:探讨慢病毒载体介导的靶向survivin基因小干涉RNA(survivin-siRNA)对裸鼠移植人肺腺癌的体内抑瘤活性。方法:构建表达survivin-siRNA的慢病毒载体和移植人肺腺癌裸鼠模型,肿瘤组织局部注射survivin-siRNA慢病毒载体,观察肿瘤体积及随时间生长变化;PI染色检测细胞凋亡;流式细胞术检测肿瘤细胞周期变化。结果:慢病毒载体介导survivin-siRNA对裸鼠肺腺癌的抑瘤率为46.07%;30～35%的肿瘤细胞凋亡;G1期细胞比例明显增加,S期细胞比例则明显减少。结论:靶向survivin的RNAi能有效抑制裸鼠移植人肺腺癌的生长,诱导肿瘤细胞凋亡和细胞周期改变。     

蓝舌病毒HbC3对几株人和动物肿瘤细胞的感染特性研究

用BTV-HbC3感染人肺癌SPC—A-1细胞,人宫颈癌HeLa细胞,人星型胶质瘤U251细胞,小鼠星形胶质瘤C6细胞及人胚肺HEL细胞后,观察细胞病变效应(CPE);运用透射电镜技术及琼脂双扩散试验检测BTV-HbC3对各种不同肿瘤细胞及人胚肺HEL细胞的感染性;并用RT-PCR技术检测蓝舌病毒的增殖情况。结果显示,BTV-HbC3对正常HEL不感染,但能在不同来源的某些肿瘤细胞中选择性增殖,产生不同程度的细胞病变效应(CPE)及调亡现象,终致肿瘤细胞死亡。其中以人肺癌SPC-A-1细胞对其最为敏感。因此,初步认为BTV-HbC3株能靶向性杀死某些肿瘤细胞,从而为深入开展BTV-HbC3靶向性抗肿瘤的研究提供了第一手实验室依据。     

单抗LC-1与针对的人肺腺癌SPC-A-1细胞肿瘤相关抗原复合物的内化研究

我们运用抗人肺癌单抗LC-1结合胶体金免疫电镜技术研究了人肺腺癌SPC-A-1细胞表面抗原抗体复合物被内吞的全过程,发现该细胞表面抗原抗体复合物是通过受体介导内吞途径被内化,经多泡体富集后至溶酶体消化降解。此外我们还用流式细胞仪分析了内吞前后该细胞表面抗原量的变化和短期内的恢复情况。LC-1在诱发该细胞表面抗原内化的同时还诱发了它对该核糖体的自噬。     

靶向抗肿瘤蛋白iRGD-CDD的原核表达及生物活性鉴定

目的: 原核表达并纯化具有特异性成纤维细胞激活蛋白(FAPα)酶切位点的靶向抗肿瘤GP-CDD-iRGD融合蛋白,利用FAPα的酶切功能切除融合标签,检测其对FAPα阳性肿瘤细胞株的毒性。方法: 设计并合成GP-CDD-iRGD基因,插入pGEX-4T3 载体,构建重组表达质粒,转化至BL21大肠杆菌感受态细胞中,IPTG诱导表达,SDS-PAGE分析重组融合蛋白的表达,Western blot检测融合蛋白的表达,经GST亲和柱纯化融合蛋白后,通过体外细胞毒性试验(MTT法)和细胞凋亡实验评价该融合蛋白的靶向抗肿瘤活性。结果: 成功构建重组原核表达质粒pGEX-GP-CDD-iRGD,可溶性表达相对分子量约为36 kDa的融合蛋白GST-GP-CDD-iRGD,纯化后蛋白纯度约为90%,经MTT实验测定其对FAPα阳性4T1细胞株的ED50约为18.5μmol/L,流式细胞术检测到其对FAPα阳性4T1细胞株具有选择性毒性作用,早期凋亡比例达到约28%。结论: 原核表达的重组融合蛋白GP-CDD-iRGD对FAPα阴性4T1细胞株未显示毒性,而对FAPα阳性4T1细胞株具有显著的促凋亡作用,为进一步研究其在体内的靶向抗肿瘤活性提供了依据。     

两种人粒酶B嵌合基因的表达及对肿瘤细胞的杀伤作用

通过重组PCR构建了抗HER2单链抗体基因、绿脓杆菌外毒素 (PE)转位肽序列和活性型粒酶B(GrBa)基因相融合的sFv2 3e PEⅡ GrBa基因 ,以及N端包含PE部分转位肽序列的PEⅡ GrBa基因 .将这 2种粒酶B嵌合蛋白基因瞬时转染或稳定转染HeLa细胞及SKBR 3细胞 .通过间接免疫荧光、细胞计数、MTT、ELISA等方法 ,观察到细胞浆中表达的PEⅡ GrBa蛋白直接杀伤其表达细胞 ;而sFv2 3e PEⅡ GrBa表达后被分泌至细胞外 ,对产生它的细胞没有杀伤性 ,但能够特异识别并杀伤HER2阳性肿瘤细胞 .结果表明 ,抗肿瘤表面抗原的抗体能够介导靶向识别 ,转位结构域可以辅助效应分子活化、转位至细胞液并杀伤细胞 ,为肿瘤的靶向治疗提供了新的策略 .     

RNA 干扰沉默缺氧诱导因子1α逆转肺癌细胞耐药性

目的:观察RNA干扰沉默缺氧诱导因子1α(HIF-1α)对肺癌细胞耐药性的影响。方法:构建靶向HIF-1α小干扰RNA基因,并转染到人肺腺癌耐顺铂细胞株A549/DDP细胞中。逆转录聚合酶链反应RT-PCR)检测细胞的HIF-1α、多药耐药基因1(MDR-1)以多药耐药相关蛋白基因(MRP)mRNA变化,免疫细胞化学法观察干扰后HIF-1α、P-糖蛋白以及MRP蛋白的变化。MTT法检测不同浓度的顺铂作用下细胞死亡率。结果:HIF-1αsiRNA组中HIF-1α、MDR-1、MRP mRNA水平显著降低(P<0.05),且蛋白水平也显著下降(P<0.05)。HIF-1αsiRNA组细胞死亡率较未转染组均明显增高(P<0.05),转染siRNA阴性组不影响肿瘤细胞的耐药性。结论:HIF-1αsiRNA可显著降低A549/DDP细胞中HIF-1α、MDR-1、MRP表达,从而起到逆转肺腺癌A549/DDP细胞的耐药作用。     

靶向DNA修复基因ERCC6的shRNA载体构建及干扰效果评价

构建靶向ERCC6基因的短发夹RNA(short hairpin RNA,sh RNA)真核表达载体,评价其对肺癌细胞ERCC6表达的干扰效果。依据ERCC6基因的核苷酸序列和小干扰RNA的设计原则,设计并合成靶向ERCC6基因的3对ERCC6-sh RNAs和1对阴性对照NC-sh RNA片段,退火后连接至表达载体p GPU6/GFP/Neo中,重组载体经测序鉴定后转染肺癌SPC-A-1细胞中观察绿色荧光蛋白的表达情况,实时荧光定量PCR和Western blotting方法检测ERCC6基因表达的变化。经测序分析证实,各ERCC6-sh RNA的表达载体均构建成功。转染重组质粒48 h后的各组细胞均有绿色荧光表达。实时荧光定量PCR和Western blotting表明,相对于阴性对照组,ERCC6-sh RNA1、ERCC6-sh RNA2、ERCC6-sh RNA3三个实验组SPC-A-1细胞中ERCC6基因在m RNA和蛋白水平上的表达均显著降低(p0.05),其中ERCC6-sh RNA3载体的干扰效果最佳。本研究成功构建并筛选了靶向ERCC6基因的sh RNA高效干扰载体,能够有效抑制ERCC6基因在肺癌细胞中的表达,这为进一步研究ERCC6基因与肿瘤发生分子机制和化疗耐药的相关性提供了帮助。     

肺鳞癌和肺腺癌FGFR融合基因的临床意义

目的:探讨肺鳞癌和肺腺癌FGFR融合基因状态及其临床病理意义。方法:采用逆转录-聚合酶链反应(RT-PCR)和直接测序的方法检测2011年1月到2013年12月在我科行手术切除治疗的肺鳞癌和肺腺癌样本的FGFR融合基因,分析患者的临床病理学资料如性别、年龄、吸烟状况、肿瘤大小、病理类型、分化程度,并与对应样本的EGFR、KRAS、HER2、BRAF等常见驱动基因突变进行比较研究。结果:入组患者共512例,包括119例鳞癌和393例腺癌。FGFR融合基因的发生频率为1.2%(6/512),该分子亚型好发于病理证实为肺鳞癌(66.7%,p=0.029)、直径大于3厘米(83.3%,p=0.029)的男性(83.3%,p=0.028)吸烟患者(83.3%,p=0.038)。腺癌融合基因样本均含有实体病理亚型。结论:FGFR融合基因是肺鳞癌和肺腺癌的重要分子亚型,可能起驱动基因作用,具有该特征的肺癌亚群患者很可能将受益于FGFR靶基因研究与靶向治疗。     

Molecular cloning and functional characterization of a cell-permeable superoxide dismutase targeted to lung adenocarcinoma cells. Inhibition cell proliferation through the Akt/p27kip1 pathway

In clinical oncology, many trials with superoxide dismutase (SOD) have failed to demonstrate antitumor ability and in many cases even caused deleterious effects because of low tumor-targeting ability. In the current research, the Nostoc commune Fe-SOD coding sequence was amplified from genomic DNA. In addition, the single chain variable fragment (ScFv) was constructed from the cDNA of an LC-1 hybridoma cell line secreting anti-lung adenocarcinoma monoclonal antibody. After modification, the SOD and ScFv were fused and co-expressed, and the resulting fusion protein produced SOD and LC-1 antibody activity. Tracing SOD-ScFv by fluorescein isothiocyanate and superoxide anions (O2*-) in SPC-A-1 cells showed that the fusion protein could recognize and enter SPC-A-1 cells to eliminate O2*-. The lower oxidative stress resulting from the decrease in cellular O2*- delayed the cell cycle at G1 and significantly slowed SPC-A-1 cell growth in association with the dephosphorylation of the serine-threonine protein kinase Akt and expression of p27kip1. The tumor-targeting fusion protein resulting from this research overcomes two disadvantages of SODs previously used in the clinical setting, the inability to target tumor cells or permeate the cell membrane. These findings lay the groundwork for development of an efficient antitumor drug targeted by the ScFv.     

The inhibition of lung cancer cell growth by intracellular immunization with LC—1 ScFv

INTRODUCTIONLung cancer remains the leading cause of can-cer mortaIity in the world, accounting for more thanone sixth of cancer deaths in the world[1]. Antibod-ies have been proved to be a powerful tool fOr thestudy of 1ung cancer. A monoclonal IgM antibody,LC-1, was obtained in our laboratory. It can reactat a high rate with all four pathological types of lungcancers, including lung adenocarcinoma, 1ung squamous carcinoma, large cell lung cancer and smaIlcell lung cancert but not wit…     

^125I标记单抗LC—I与肺腺癌细胞体内外结合特性的研究

McAb LC-1 was derived from fusion of myeloma cells and murine spleen cells immunized with human lung adenocarcinoma SPC-A-1 cells. The immunoglobulin isotype of LC-1 belonged to IgM. LC-1 was direct against the common epitope of lung cancer. It not only reacted with small cell lung cancer but also with non small cell lung cancer. LC-1 was purified from ascitic fluid by euglobulin precipitation and Sephadex G-200 filtration chromatography, and was iodinated with Iodogen, the specific reactivity of 125I-labeled LC-1 was determined by comparing standard curve with self-displacement curve. The immunoreactive fraction of 125I-LC-1 was determined by its binding to excess of antigen. The RIA data were plotted in Scatchard-form as binding of SPC-A-1 cells to LC-1. The binding constant of LC-1 binding to SPC-A-1 was 4.8 x 10(8) M-1. The LC-1 binding sites on SPC-A-1 were 7.2 x 10(4) per cell. The RIA inhibition test showed that LC-1 and LAC-122 (another IgM isotype McAb reacted only with non small cell lung cancer) had no cross-reactivity. The treatment of SPC-A-1 cells by proteinase and sodium periodate inhibited LC-1 binding to these treated target cells by 39% and 66% respectively. These results suggested that the biochemical nature of antigen recognized by LC-1 was glycoprotein.(ABSTRACT TRUNCATED AT 250 WORDS)     

Studies on antigens of human lung adenocarcinoma with McAb LC-1]

The soluble antigens extracted from both human lung adenocarcinoma cell line SPC-A-1, and normal adult lung tissue with non-idet P-40 were subjected to 10% SDS-PAGE. The number of bands distinguishable by naked eyes of lung adenocarcinoma are 57, in which 4 bands are more significant. The bands of normal human lung tissue are 52, in which 2 bands are more significant. The molecular weights of these bands mainly are within 30 to 94 KD The thin layer chromatographs of these two antigenic extracts have shown that there is difference in their sugar content, but both of them shown little sialic acid. The Immunoblot pattern of McAb LC-1 reacted with the extracts of SPC-A-1 cells shows that all of 3 bands detected can be stained by alcian blue, indicating that they are glycoproteins. However, of them two bands, M. W. of 70 KD and 51 KD can also be stained by Sudan Black B, indicating that these two bands are glycolipoproteins. The ganglioside and neutral glycolipid can inhibit the binding of LC-1 with the extract of SPC-A-1 cells. The results indicate that the epitopes of SPC-A-1 cell extract reacted with McAb LC-1 are probably located in the polysaccharide.     

McAb LC-1 against human lung cancer

Recently Ge et al reported LAC-122, LAC-210 and LAC-163 McAbs against Human non-small cell lung cancer and LSC McAbs against human lung small cell carcinoma. The immunotoxin, composed of McAb LAC-122 conjugated with Ricin A chain has been reported to have the significant cytotoxic effect in vitro on lung adenocarcinoma cell line SPC-A-1 by Tan et al. The LAC-122 alone has no effect on this target cell in the presence of complement from human, rabbit or guinea pig. The tumor associated antigens of human lung cancer have been recognized for many years, but only few reports deal with the common antigens or common epitopes of the lung cancer. From one fusion, 20 hybrids had been observed, all of these culture supernatants could react with target cell by IF. One of them after 4 th cloning, immunoglobulin isotype of the monoclonal antibody thus far obtained belonged to IgM and named to LC-1. Table 1 showed the results of ABC staining of LC-1 with a variety of tumors, normal adult and fetal tissues. From 12 non-small cell lung cancers, including 7 lung adenocarcinoma, 2 lung squamous carcinoma, 3 lung giant cell carcinoma, only one adenocarcinoma gave negative staining. As for 6 small cell lung cancers, all of them showed the positive reaction. It could be also reacted with 11 other tumors.(ABSTRACT TRUNCATED AT 250 WORDS)     

Preparation and characterization of recombinant protein ScFv(CD11c)-TRP2 for tumor therapy from inclusion bodies in Escherichia coli

Dendritic cells (DCs)-based immunotherapy represents an approach to the prevention and treatment of cancers. Targeting antigens to receptors on DCs can be expected to enhance immune response. We have constructed an expression vector pET32a(+)-ScFv(CD11c)-TRP2 based on a single-chain antibody fragment (ScFv) that targets the high affinity receptor CD11c which is expressed on murine DCs. The 3'-terminal end of the ScFv was ligated to the gene for MHC class I molecule-recognized peptide from mouse tyrosine-related protein 2 (TRP2). Using this vector, we have expressed and purified ScFv(CD11c)-TRP2, a fusion protein that could target TRP2 peptide to CD11c on DCs in vivo to elicit anti-tumor responses. This fusion protein was expressed in inclusion bodies in Escherichia coli BL21(DE3) and was refolded and purified on-column effectively by immobilized metal affinity chromatography using His-tag. Flow cytometry assays showed the specific binding ability of ScFv(CD11c)-TRP2 to DCs, which could be blocked by a hamster anti-mouse CD11c produced by N418 hybridoma. Further studies demonstrated that ScFv(CD11c)-targeted TRP2 peptide processed by DCs was capable of stimulating T cells proliferation. Thus, this fusion protein provides a basis for further research in cancer therapy in vivo.     

9-polylysine protein transduction domain: enhanced penetration efficiency of superoxide dismutase into mammalian cells and skin

Antioxidant enzymes, such as superoxide dismutase (SOD) and catalase (CAT), have been considered to have a beneficial effect against various diseases that are mediated by the reactive oxygen species (ROS). Although a variety of modified recombinant antioxidant enzymes have been generated to protect against oxidative stresses, the lack of their transduction ability into cells resulted in a limited ability to detoxify intracellular ROS. To render the SOD enzyme capable of detoxifying intracellular ROS when added extracellularly, cell-permeable recombinant SOD proteins were generated. A human Cu,Zn-superoxide dismutase (Cu,Zn-SOD) gene was fused with a gene fragment that encodes the 9 amino acids Tat protein transduction domain (RKKRRQRRR) of HIV-1 and lysine rich peptide (KKKKKKKKK) in a bacterial expression vector in order to produce a genetic in-frame Tat-SOD and 9Lys-SOD fusion protein, respectively. The expressed and purified Tat-SOD and 9Lys-SOD fusion proteins can transduce into human fibroblast cells, and they were enzymatically active and stable for 24 h. The cell viability of the fibroblast cells that were treated with paraquat, an intracellular superoxide anion generator, was increased by the transduced Tat-SOD or 9Lys-SOD. The transduction efficacy of 9Lys-SOD was more efficient than that of Tat-SOD. We evaluated the ability of the SOD fusion pmteins to transduce into animal skin. This analysis showed that Tat-SOD and 9Lys-SOD fusion proteins efficiently penetrated into the epidermis as well as the dermis of the subcutaneous layer, when sprayed on mice skin (judged by the immunohistochemistry and specific enzyme activities). The enzymatic activity of the transduced 9Lys-SOD was higher than that of Tat-SOD, indicating that the penetration of 9Lys-SOD was more efficient when put into the skin. These results suggest Tat-SOD and 9Lys-SOD fusion proteins can be used as anti-aging cosmetics, or in protein therapy, for various disorders that are related to this antioxidant enzyme and ROS.     

Transduction of human catalase mediated by an HIV-1 TAT protein basic domain and arginine-rich peptides into mammalian cells.

Antioxidant enzymes such as superoxide dismutase (SOD) and catalase (CAT) have been considered to have a beneficial effect against various diseases mediated by reactive oxygen species (ROS). Although a variety of modified recombinant antioxidant enzymes have been generated to protect against the oxidative stresses, the lack of their transduction ability into cells resulted in limited ability to detoxify intracellular ROS. To render the catalase enzyme capable of detoxifying intracellular ROS when added extracellularly, cell-permeable recombinant catalase proteins were generated. A human liver catalase gene was cloned and fused with a gene fragment encoding the HIV-1 Tat protein transduction domain (RKKRRQRRR) and arginine-rich peptides (RRRRRRRRR) in a bacterial expression vector to produce genetic in-frame Tat-CAT and 9Arg-CAT fusion proteins, respectively. The expressed and purified fusion proteins can be transduced into mammalian cells (HeLa and PC12 cells) in a time- and dose-dependent manner when added exogenously in culture medium, and transduced fusion proteins were enzymatically active and stable for 60 h. When exposed to H(2)O(2), the viability of HeLa cells transduced with Tat-CAT or 9Arg-CAT fusion proteins was significantly increased. In combination with transduced SOD, transduced catalase also resulted in a cooperative increase in cell viability when the cells were treated with paraquat, an intracellular antioxide anion generator. We then evaluated the ability of the catalase fusion proteins to transduce into animal skin. This analysis showed that Tat-CAT and 9Arg-CAT fusion proteins efficiently penetrated the epidermis as well as the dermis of the subcutaneous layer when sprayed on animal skin, as judged by immunohistochemistry and specific enzyme activities. These results suggest that Tat-CAT and 9Arg-CAT fusion proteins can be used in protein therapy for various disorders related to this antioxidant enzyme.     

Mn-SOD与抗癌胚抗原单链抗体基因的融合及高效表达

将Ｍｎ－ＳＯＤ与抗癌胚抗原（ＣＥＡ）单链抗体基因（Ｓｃ－Ｆｖ ｇｅｎｅ）融合,重组到含Ｔ７启动子的表达载体ｐＥＴ－２２ｂ（＋）中,构建表达质粒ｐＥＴＭｎ－ＳＯＤ－ＳｃＦｖ,并转化大肠杆菌ＢＬ２１（ＤＥ３）,进行高效表达,表达物占菌体可溶性总蛋白的２４％。ＳＤＳ－ＰＡＧＥ和蛋白质和迹图谱显示表达物分子量为４５ｋＤ与融合基因编码蛋白质的理论值相符。该蛋白质在大肠杆菌中为泌型表达有利于纯化。ＲＩＡ测定表     

In vivo protein transduction: biologically active intact pep-1-superoxide dismutase fusion protein efficiently protects against ischemic insult

Reactive oxygen species (ROS) are implicated in reperfusion injury after transient focal cerebral ischemia. The antioxidant enzyme Cu,Zn-superoxide dismutase (SOD) is one of the major means by which cells counteract the deleterious effects of ROS after ischemia. Recently, we reported that denatured Tat-SOD fusion protein is transduced into cells and skin tissue. Moreover, PEP-1 peptide, which has 21 amino acid residues, is a known carrier peptide that delivers full-length native proteins in vitro and in vivo. In the present study, we investigated the protective effects of PEP-1-SOD fusion protein after ischemic insult. A human SOD gene was fused with PEP-1 peptide in a bacterial expression vector to produce a genetic in-frame PEP-1-SOD fusion protein. The expressed and purified fusion proteins were efficiently transduced both in vitro and in vivo with a native protein structure. Immunohistochemical analysis revealed that PEP-1-SOD injected intraperitoneally (i.p.) into mice can have access into brain neurons. When i.p.-injected into gerbils, PEP-1-SOD fusion proteins prevented neuronal cell death in the hippocampus caused by transient forebrain ischemia. These results suggest that the biologically active intact forms of PEP-1-SOD provide a more efficient strategy for therapeutic delivery in various human diseases related to this antioxidant enzyme or to ROS, including stroke.